Phase Ib Clinical Trial of IGV-001 for Patients with Newly Diagnosed Glioblastoma.
David William AndrewsKevin D JudyCharles B ScottSamantha GarciaLarry A HarshyneLawrence C KenyonKiran TalekarAdam E FlandersKofi-Buaku AtsinaLyndon KimNina MartinezWenyin ShiMaria Werner-WasikHaisong LiuMikhail ProsniakMark CurtisRhonda KeanDonald Y YeEmily BongiornoSami SaumaMark A ExleyKara PigottD Craig HooperPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
IGV-001 was well tolerated, PFS compared favorably with SOC, and evidence suggested an immune-mediated mechanism (ClinicalTrials.gov: NCT02507583).